Erlangen, Germany
AB-CT - Advanced Breast-CT is a medical technology company aiming to revolutionize breast cancer diagnosis with its innovative product, nu:view. The company's slogan "Our vision is to empower radiologists to diagnose breast cancer with confidence at the earliest possible stage" reflects its commitment to improving healthcare outcomes. AB-CT's nu:view is the world's first breast CT scanner utilizing spiral CT technology, capable of generating high-quality 3D images without compression and with low radiation dose.
Founded in 2016, AB-CT operates in the Health Care, Medical Devices, and VR/AR industries. It prides itself on prioritizing patient comfort, as nu:view allows for a pain-free examination process with a focus on reassurance. However, it's important to note that while nu:view has received CE approval, it is yet to obtain FDA approval, limiting its market reach.
With the potential to significantly impact breast cancer diagnosis, AB-CT's nu:view is a promising innovation. However, further expansion will depend on securing investment. Currently, details regarding the company's last investment and investors remain undisclosed. For interested investors, AB-CT's potential for disruption in the medical technology space is certainly worth exploring.
For more information, interested parties are encouraged to reach out to AB-CT directly to check the availability of nu:view in their respective territories. The company's ambition to enhance breast cancer diagnosis through cutting-edge technology positions it as an intriguing prospect for potential investors seeking opportunities in the health tech sector.
Imprint: https://www.ab-ct.com/imprint/
